Inquiry Basket
Loading ......
The Omni-Hybridoma™ Platform is a revolutionary approach to monoclonal antibody development that overcomes traditional hybridoma technology's major limitations. The Omni-Hybridoma™ Platform delivers groundbreaking advancements that transform the cultivation and selection of hybridoma cells through its innovative subcloning method. The platform functions to enhance the generation of monoclonal antibodies which serve important roles in both therapeutic applications and diagnostic procedures.
The creation of monoclonal antibodies marks an essential advancement in biotechnology because it allows for precise treatment options across various diseases like cancer and autoimmune disorders as well as infectious diseases. The hybridoma technique stands as a top method for monoclonal antibody production. Traditional hybridoma cloning techniques such as the limited dilution method consume excessive time are inefficient, which results in the elimination of potentially beneficial slow-growing clones. The Omni-Hybridoma™ Platform resolves these issues through its innovative hybridoma cloning and selection method which guarantees complete clone isolation and evaluation at the initial stage.
Omni-Hybridoma™ platform provides a comprehensive solution for monoclonal antibody research and production, making the Omni-Hybridoma™ Platform a valuable asset for both academic and industrial applications.
The core of the Omni-Hybridoma™ Platform is its agarose-based semi-solid medium, which is specifically formulated to support the growth and differentiation of hybridoma cells.
One of the most significant advantages of the Omni-Hybridoma™ Platform is its ability to select and clone hybridoma cells immediately after fusion.
The platform is designed to maximize cloning efficiency by ensuring that each hybridoma cell is isolated and grown in a distinct colony.
The Omni-Hybridoma™ Platform is not a standalone solution but is integrated with a suite of advanced technologies and services that enhance the overall workflow of monoclonal antibody development.
| Parameter | Traditional Method | Omni-Hybridoma™ |
| Cloning Efficiency | 20-50 clones/fusion | 1,500+ clones/fusion |
| Time to Clones | 4-6 weeks | 7-10 days |
| Clone Loss Rate | >90% | <5% |
| Labor Intensity | High (multiple dilutions) | Automated |
Biotechnology and biomedical research sectors use the Omni-Hybridoma™ Platform for multiple applications, including but not limited to:
The Omni-Hybridoma™ Platform produces monoclonal antibodies that serve as treatments for cancer and autoimmune diseases while also being used for infectious disease prevention through antiviral antibody production.
The platform aids in producing diagnostic antibodies with high specificity for disease identification through immunoassays such as ELISA and lateral flow tests as well as immunohistochemistry (IHC).
This research allows scientists to study fundamental antibody-antigen binding processes and immune response pathways while exploring new therapeutic possibilities.
The Omni Hybridoma™ Platform is part of a broader ecosystem of services and technologies that support the entire lifecycle of monoclonal antibody development. These services include:
Our expert team provides top - notch hybridoma cell fusion services using the Omni-Hybridoma™ Platform. We carefully prepare the cells, select the most suitable fusion conditions, and ensure that the fusion process is carried out with the highest level of precision. Our exclusive Magic™ mouse adjuvant is a game - changer in immunostimulation, capable of triggering a more potent and rapid immune response. The Magic™ hybridoma growth factor is a remarkable innovation, effectively enhancing the cloning efficiency.
Once the hybridoma cells are fused, we offer comprehensive subcloning and selection services, enhanced by our custom hybridoma optimization service which tailors the process according to your unique research requirements. Using the agarose - based semi-solid medium, we subclone the newly fused hybridoma cells and grow them in an environment that promotes the growth of single - cell derived clones. Our selection process is designed to identify and isolate the hybridoma clones that secrete the antibodies of interest.
Our services include comprehensive antibody screening and characterization procedures. We employ screening technologies that enable us to rapidly and precisely pinpoint antibodies that exhibit the required specificity and affinity. Following antibody identification we perform comprehensive characterization to assess their binding properties as well as their isotype and functional activity. Understanding the potential applications of antibodies in therapeutic or diagnostic settings requires this information.
We offer antibody development projects that are tailored to meet the specific requirements of each research project which may need polyclonal antibodies for initial screening or monoclonal antibodies for precise applications. Our team establishes close collaboration with clients to identify their unique requirements and project goals as well as their timelines. We develop and implement a customized antibody development strategy through the Omni-Hybridoma™ Platform. We offer comprehensive end-to-end support from animal immunization through to monoclonal antibody production to guarantee successful project completion aligned with client expectations.
We immunize host animals with the target antigen, followed by careful isolation and preparation of splenocytes for subsequent fusion.
Using polyethylene glycol (PEG) or electrofusion techniques, we fuse the prepared splenocytes with myeloma cells to generate hybridoma cells.
The fused cells are cultured in HAT medium to selectively eliminate unfused parental cells, while our agarose-based semi-solid medium enables the cloning of viable hybridomas from single cells.
We employ high-throughput screening methods, such as ELISA or flow cytometry, to identify hybridoma clones secreting antibodies with the desired specificity and affinity.
Once validated, the selected clones undergo scale-up in bioreactors for large-scale antibody production, followed by purification and rigorous quality control testing.
Figure 11. Detection of the binding activity of antibodies developed using the Omni-Hybridoma™ Platform to different epitopes of the target antigen.
The Omni-Hybridoma™ Platform showcases multiple significant distinctions when compared to traditional hybridoma techniques. Traditional hybridoma cloning methods need repeated limited dilution steps to isolate monoclonal clones but this method takes a long time and requires much effort while frequently discarding slow-growing valuable clones. Our platform utilizes an agarose-based semi-solid medium combined with optimized supplements to enable instant selection of hybridoma cell clones right after fusion. The platform establishes clonal purity initially, demonstrates high throughput capacity and merges both HAT selection with cloning into one step that leads to increased productivity and yield of hybridoma clones.
The Omni-Hybridoma™ Platform provides high flexibility for creating numerous antibodies such as therapeutic monoclonal antibodies targeting cancer treatment and autoimmune disease therapy along with antibodies for infectious disease prevention. This platform enables researchers to create diagnostic antibodies for disease detection and antibodies that are solely for scientific research purposes.
Several factors including project complexity and immunogen nature as well as client requirements determine the duration needed to acquire hybridoma clones. The Omni-Hybridoma™ Platform delivers substantial time savings over traditional methods for this entire process. The entire procedure from cell fusion through to the isolation of enough hybridoma clones for screening now takes only several weeks using Omni-Hybridoma™ instead of the multiple months required through traditional methods.
Loading ......
